SCHEMBL197898

SCHEMBL197898

COC(=O)c1c(C)cc(O)cc1C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.81
ACHE P22303 2/20 0.81
HPGD P15428 3/20 0.63
CA12 O43570 5/20 0.56
CA1 P00915 5/20 0.56
CA2 P00918 5/20 0.56
CA7 P43166 5/20 0.56
CA9 Q16790 5/20 0.56
CA14 Q9ULX7 5/20 0.56
TDP1 Q9NUW8 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GLO1 Q04760 1/20 0.50
POLB P06746 5/20 0.49
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
RECQL P46063 2/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Orsellinate SCHEMBL370816 0.90 CYP3A4 (1.00) CYP3A4ACHEHPGDCA12CA1
SCHEMBL20503232 0.86 CYP3A4 (0.68) CYP3A4ACHEHPGDCA12CA1
SCHEMBL23484417 0.86 CYP3A4 (0.68) CYP3A4ACHEHPGDCA12CA1
SCHEMBL1036031 0.84 CYP3A4 (0.59) CYP3A4ACHEHPGDCA12CA1
SCHEMBL2662948 0.82 CYP3A4 (0.62) CYP3A4ACHEHPGDCA12CA1
SCHEMBL70139 0.82 CYP3A4 (0.57) CYP3A4ACHEHPGDCA12CA1
SCHEMBL28768602 0.81 CYP3A4 (0.61) CYP3A4ACHEHPGDCA12CA1
SCHEMBL10073228 0.80 CYP3A4 (0.55) CYP3A4ACHEHPGDCA12CA1
SCHEMBL610098 0.80 CYP3A4 (0.55) CYP3A4ACHEHPGDCA12CA1
SCHEMBL11067587 0.80 CYP3A4 (0.79) CYP3A4ACHEHPGDCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN claimed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
CN-122060466-A Comb type polymer modified barite powder and preparation method and application thereof 中国石油集团渤海钻探工程有限公司 2026-05-19 CN disclosed
US-12486258-B2 Compounds and methods for regulating insulin secretion THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
US-12421452-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2025-09-23 US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 EP disclosed
US-20250228811-A1 Triester Compounds And Methods Of Use Thereof LIFEMINE THERAPEUTICS, INC. 2025-07-17 US disclosed
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN disclosed
US-20240084196-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-03-14 US disclosed
US-11884864-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-01-30 US disclosed
EP-0594257-B1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC (US) 1996-07-10 EP disclosed
US-5512589-A TREATING DEGENERATIVE DISEASES STERLING WINTHROP INC. (US) 1996-04-30 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
EP-0594257-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1994-04-27 EP disclosed
US-5306818-A Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis STERLING WINTHROP INC. (US) 1994-04-26 US disclosed
US-5157018-A Phenolic resins; for waterless offset printing plates HOECHST AKTIENGESELLSCHAFT (DE) 1992-10-20 US disclosed
US-5104961-A Waterless offset printing HOECHST CELANESE CORPORATION (US) 1992-04-14 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-5006443-A Radiation sensitive reproduction composition and element with perfluoroalkyl group containing polymer HOECHST AKTIENGESELLSCHAFT (DE) 1991-04-09 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486258-B2 Compounds and methods for regulating insulin secretion IAPP, GPR119, PNLIP CYP3A4 4626/4885ACHE 3202/4885HPGD 2210/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 CYP3A4 1190/4885ACHE 3231/4885HPGD 1044/4885
US-20250228811-A1 Triester Compounds And Methods Of Use Thereof CYP46A1, CYP17A1, CYP27A1 CYP3A4 104/4885ACHE 1179/4885HPGD 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.